📰 Daniel Tass News
Page 2 - Daniel Tass News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Daniel Tass. Real-time updates on events, politics, business and more.
April 19, 2023
Montrouge, France, April 19, 2023 DBV Technologies Outlines Regulatory Path for Viaskin Peanut in Children 1 - 3 Years After Receiving Pre-BLA Responses from FDA The FDA confirmed that the
April 19, 2023
Montrouge, France, April 19, 2023 DBV Technologies Outlines Regulatory Path for Viaskin Peanut in Children 1 – 3 Years After Receiving Pre-BLA Responses from FDA The FDA confirmed that the... | April 19, 2023
March 6, 2023
Operator: Good day, and welcome to the DBV Technologies Full Year 2022 Financial Results Conference Call. Please note this event is being recorded. I would now like to turn the conference over to Ms.
September 7, 2022
Montrouge, France, September 7, 2022 DBV Technologies Announces Initiation of Phase 3 Study (VITESSE) Using the Modified Viaskin Peanut Patch in Peanut -Allergic Children Ages 4 to 7
September 2, 2022
Montrouge, France, September 2, 2022 DBV Technologies to Present at Upcoming Investor Conferences DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage
June 7, 2022
Montrouge, France, June 7, 2022 DBV Technologies Announces Positive Topline Results from Phase 3 EPITOPE Trial of Viaskin Peanut in Peanut-Allergic Toddlers 67.0% of subjects treated with Viaskin...
June 7, 2022
Montrouge, France, June 7, 2022 DBV Technologies Announces Positive Topline Results from Phase 3 EPITOPE Trial of Viaskin Peanut in Peanut-Allergic Toddlers 67.0% of subjects treated
January 7, 2022
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
November 24, 2021
DBV Technologies to Participate in an Upcoming Investor Conference | Regulatory News
March 5, 2021
DBV Technologies S.A.: DBV Technologies to Participate in the H.C. Wainwright Global Life Sciences Conference DBV Technologies to Participate in the H.C. Wainwright Global Life Sciences Conference DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel Tassé, Chief Executive Officer, will present at the H.C. Wainwright Global Life Sciences Conference being held March 9-10, 2021. A webcast of the ...